Clinical Guides
Type 2 Diabetes Mellitus
A clinically focused guide to confirming and classifying type 2 diabetes, assessing cardiovascular, kidney and microvascular risk, individualising lifestyle, weight, medicines and targets, and delivering sustainable care in India.
MedNext Academy | 14 min read
Type 2 Diabetes Mellitus
A clinically focused guide to confirming and classifying type 2 diabetes, assessing cardiovascular, kidney and microvascular risk, individualising lifestyle, weight, medicines and targets, and delivering sustainable care in India.
Summary
Type 2 diabetes mellitus is a heterogeneous chronic metabolic disease in which insulin resistance and progressive beta-cell dysfunction produce persistent hyperglycaemia. It is not diagnosed from obesity, family history, glycosuria, or one screening-capillary value. Diagnosis uses validated laboratory thresholds, with confirmation when symptoms or unequivocal hyperglycaemia are absent. Classification remains revisable because autoimmune, monogenic, pancreatic, drug-induced, and pregnancy-related diabetes can initially resemble type 2 disease.
Good care has four linked aims: relieve symptomatic hyperglycaemia, prevent acute crisis, reduce microvascular injury, and lower cardiovascular, kidney, and heart-failure risk while preserving quality of life. Glucose is only one part. Blood pressure, lipids, smoking, weight, kidney disease, retinopathy, neuropathy, foot risk, vaccination, mental health, sleep, and access to care require an organised review. HbA1c below 7% is appropriate for many non-pregnant adults, but a number is not automatically safe for a frail person with recurrent hypoglycaemia or necessarily optimal for a younger person who can achieve lower glucose without harm.
Lifestyle support and weight management begin at diagnosis and continue with medicine. Drug choice is individualised by atherosclerotic cardiovascular disease, heart failure, CKD, weight goals, hypoglycaemia, renal and liver function, pregnancy potential, adverse effects, cost, and reliable supply. Metformin remains effective, inexpensive, and widely used, but contemporary care may prioritise an SGLT2 inhibitor or GLP-1-based therapy for organ protection in eligible people. Insulin is indicated for crisis, catabolism, severe symptomatic hyperglycaemia, pregnancy, or inadequate control when it is the safest practical option.
How Common Is It?
Type 2 diabetes accounts for most diabetes worldwide, but “most” should not be converted into a precise local percentage without a defined population and ascertainment method. India has a large and geographically uneven burden of diagnosed and undiagnosed diabetes. Community surveys, laboratory cohorts, insurance records, and NP-NCD registers measure different things. Urban-rural differences are changing, and prevalence varies by age, sex, adiposity, socioeconomic conditions, state, migration, and diagnostic test. A single national number cannot safely describe every district or clinical service.
The burden extends beyond people who have reached a diagnostic threshold. Prediabetes and cardiometabolic risk are common, while delayed detection allows retinopathy, albuminuria, neuropathy, or cardiovascular disease to be present at diagnosis. Conversely, indiscriminate screening without quality-assured confirmation and follow-up can mislabel people and consume limited resources. NP-NCD supports population-based screening from age thirty and structured primary-care pathways, but a risk score or point-of-care screen is an entry to assessment, not the final diagnosis.
Local services should track the proportion of screen-positive people receiving confirmatory testing, time to treatment of symptomatic hyperglycaemia, HbA1c and blood-pressure follow-up, UACR and eGFR assessment, retinal screening, foot-risk documentation, statin eligibility review, medicine availability, and loss to follow-up. These measures identify actionable gaps more reliably than claiming that one prevalence estimate proves service quality.
Risk Factors
Risk rises with age, family history in a first-degree relative, South Asian ancestry, overweight or central adiposity, physical inactivity, hypertension, dyslipidaemia, cardiovascular disease, prediabetes, gestational diabetes, delivery of a large baby, polycystic ovary syndrome, acanthosis nigricans, sleep disorders, and medicines such as glucocorticoids or some antipsychotics. HIV treatment, endocrine disorders, pancreatic disease, and social conditions that restrict access to healthy food or safe activity can add risk. Lean people can develop type 2 diabetes, particularly in South Asian populations; BMI alone is an inadequate gatekeeper.
Risk assessment should distinguish probability of disease from certainty of diagnosis. Polyuria, polydipsia, blurred vision, recurrent infection, weight loss, or delayed wound healing require diagnostic testing rather than a score. Acute illness and glucocorticoids may reveal pre-existing dysglycaemia or cause transient hyperglycaemia. A history of ketosis, very rapid symptom onset, marked catabolism, autoimmune disease, or unexpectedly early treatment failure raises concern for insulin deficiency rather than ordinary type 2 disease.
Complication risk is shaped by duration of hyperglycaemia, blood pressure, albuminuria, eGFR, lipids, smoking, prior cardiovascular disease, foot risk, retinopathy, and treatment access. Hypoglycaemia risk increases with insulin or secretagogues, kidney impairment, irregular meals, alcohol, frailty, and cognitive limitations. Ask about pregnancy intention, food insecurity, medication cost, shift work, fasting practices, and travel. These factors change the safe plan even though they are not biochemical diagnostic criteria.
Diagnosis
History
Ask about polyuria, polydipsia, nocturia, weight change, fatigue, blurred vision, recurrent genital or skin infection, neuropathic symptoms, erectile dysfunction, pregnancy, and acute features of DKA or HHS. Establish onset and tempo; family history; gestational diabetes; pancreatitis, pancreatic surgery, haemochromatosis, cystic fibrosis, endocrinopathy, steroid or antipsychotic exposure; and autoimmune disease. Record cardiovascular, kidney, eye, foot, smoking, diet, activity, sleep, mental health, alcohol, medicines, affordability, and prior laboratory results.
Examination
Measure blood pressure correctly and assess hydration, mental state, weight trend, BMI and waist where useful, acanthosis, injection sites if relevant, pulses, skin, feet, and neuropathy. Look for infection, peripheral arterial disease, ulceration, Charcot change, retinopathy-related visual limitation, endocrine stigmata, and evidence of catabolism. Examination cannot confirm type 2 diabetes but can reveal crisis, complications, or a competing cause that changes urgency.
Investigations
Diagnostic thresholds in non-pregnant adults are HbA1c at least 6.5%, fasting plasma glucose at least 126 mg/dL, two-hour plasma glucose at least 200 mg/dL during a 75-g OGTT, or random plasma glucose at least 200 mg/dL with classic symptoms or hyperglycaemic crisis. Without unequivocal hyperglycaemia, confirm promptly using a repeat of the same test or a second diagnostic test. Use quality-assured laboratory methods. HbA1c may mislead in anaemia, haemoglobin variants, altered red-cell turnover, pregnancy, transfusion, and some kidney states.
At or soon after confirmation, obtain renal function and UACR, lipids, liver assessment, blood pressure, foot-risk evaluation, and retinal-screening referral. Test ketones, venous gas, electrolytes, and osmolality urgently when crisis is possible. Autoantibodies, C-peptide interpreted with concurrent glucose, pancreatic imaging, or genetic testing are selected classification tools, not routine barriers to starting necessary treatment.
Differential Diagnosis
Type 1 diabetes can present at any adult age and in a person with overweight. Rapid symptoms, weight loss, ketosis, low endogenous insulin secretion, personal autoimmunity, or unexpectedly rapid failure of non-insulin therapy should trigger urgent reclassification. Latent autoimmune diabetes in adults is not a reason to postpone insulin when deficiency is evident. Ketosis-prone diabetes may later recover some secretion but initially requires crisis-safe management. Gestational diabetes and overt diabetes first recognised in pregnancy use pregnancy-specific testing and treatment pathways.
Monogenic diabetes should be considered with young onset, multigenerational autosomal-dominant patterns, atypical features, or neonatal diabetes; correct diagnosis may change treatment and family counselling. Pancreatogenic diabetes follows chronic pancreatitis, pancreatic cancer, cystic fibrosis, haemochromatosis, or pancreatic surgery and may combine insulin deficiency with malabsorption. Drug-related hyperglycaemia can follow glucocorticoids, some antipsychotics, immunosuppressants, and immune-checkpoint inhibitors. Cushing syndrome, acromegaly, hyperthyroidism, and other endocrinopathies are uncommon but clinically directed differentials.
Stress hyperglycaemia during sepsis, myocardial infarction, stroke, trauma, or surgery may be transient, but it predicts future diabetes and requires follow-up. Renal glycosuria and SGLT2 therapy can cause urinary glucose without diagnostic blood hyperglycaemia. Laboratory interference, incorrect fasting, and acute changes in red-cell turnover can create discordant results. DKA and HHS must be actively excluded when vomiting, dehydration, ketones, acidosis, severe hyperglycaemia, or altered consciousness appears; do not wait for perfect classification before emergency treatment.
Management
Agree priorities with the person and provide structured diabetes self-management education. Nutrition advice should emphasise a sustainable dietary pattern, adequate protein and micronutrients, minimally processed foods, fibre, vegetables, pulses and whole grains where affordable, and reduction of sugar-sweetened drinks and refined excess. It should adapt portion and carbohydrate distribution to regional staples rather than prohibiting rice or roti without a workable replacement. Encourage progressive aerobic and resistance activity, less sedentary time, adequate sleep, and smoking cessation, accounting for foot disease, cardiovascular symptoms, frailty, and occupational exertion.
Weight management is a treatment goal, not a prerequisite for respectful care. Discuss an achievable initial trajectory, waist and functional outcomes, and relapse without blame. Intensive lifestyle programmes, anti-obesity medicines, and metabolic surgery may be appropriate for selected people under current criteria, but affordability and long-term follow-up matter. Avoid crash diets in people using insulin or sulfonylureas without medication review because hypoglycaemia can follow rapid dietary change.
Start pharmacotherapy at diagnosis unless a short, monitored lifestyle-first approach is genuinely appropriate and safe. Individualise by cardiovascular disease, heart failure, CKD, weight, hypoglycaemia, eGFR, liver disease, pregnancy, cost, and preference. Metformin is often a practical foundation. In people with established or high-risk cardiovascular disease, CKD, or heart failure, use an evidence-based SGLT2 inhibitor and/or GLP-1 receptor agonist where indicated, tolerated, licensed, and accessible, independent of whether additional HbA1c lowering is the only need. Reassess rather than stacking drugs indefinitely.
For many non-pregnant adults, HbA1c below 7% is reasonable; use a lower goal only if achievable without significant hypoglycaemia or burden, and a less stringent goal with frailty, limited life expectancy, cognitive impairment, severe comorbidity, or high treatment harm. Repeat HbA1c roughly every three months when therapy changes or control is unstable and less often when stable, adjusted to local capacity. Monitor home glucose when it will alter a decision, especially with insulin, secretagogues, symptoms, pregnancy, illness, or driving risk.
At every cycle, manage blood pressure and lipids, review vaccination and oral health, screen distress and depression, and address eyes, kidneys, neuropathy and feet. Acute illness requires hydration advice, more frequent glucose checks, ketone testing when DKA is possible, and written medicine pause/restart rules. Pregnancy planning requires preconception review and transition away from unsuitable medicines before conception.
Prescribing Information
Metformin is effective, inexpensive, and widely available. Start low and titrate to tolerance according to the local formulary. Gastrointestinal effects are common; extended-release formulations may help some people. Do not use it when eGFR is below 30 mL/min/1.73 m², review dose and risk as renal function falls, and temporarily reassess during acute hypoxia, shock, severe dehydration, or major renal deterioration. Long-term therapy can contribute to vitamin B12 deficiency, so test when anaemia or neuropathy is unexplained and consider periodic assessment in at-risk patients.
SGLT2 inhibitors offer heart-failure and kidney benefit in appropriate patients, but product eGFR thresholds, indications, and access differ. Counsel about genital mycotic infection, volume depletion, and ketoacidosis that may occur with only moderate glucose. Provide pause rules for prolonged fasting, severe acute illness, and selected procedures, and urgent ketone assessment for nausea, abdominal pain, or deep breathing. GLP-1 receptor agonists and dual incretin therapy can improve glucose and weight and selected agents reduce cardiovascular risk; gastrointestinal effects, gallbladder disease, product-specific contraindications, cost, and pregnancy plans matter.
Sulfonylureas are accessible and potent but cause hypoglycaemia and weight gain; choose and dose carefully in older adults, irregular eaters, drivers, and CKD. DPP-4 inhibitors have modest glucose effects and product-specific renal adjustments; do not combine a DPP-4 inhibitor with GLP-1-based therapy because it adds little glucose benefit. Pioglitazone can cause weight gain, oedema, and heart-failure worsening and needs fracture and bladder-risk consideration. Insulin is appropriate for crisis, catabolism, marked symptomatic hyperglycaemia, pregnancy, or failure of a safe non-insulin plan; initiation must include technique, monitoring, titration, hypoglycaemia, and supply education.
Do not treat glucose in isolation. ACE inhibitors or ARBs have defined roles in non-pregnant people with hypertension and albuminuria; statin intensity is based on age and cardiovascular risk; antiplatelet treatment is not automatic primary prevention. Review all prescribing in pregnancy. Generic availability, fixed-dose combinations, brands, and renal thresholds vary in India. Write the indication, target, monitoring, adverse-effect safety net, affordability check, review date, and plan if the medicine becomes unavailable.
When to Refer
Send for emergency assessment when DKA or HHS is possible: vomiting, abdominal pain, deep breathing, ketonaemia, severe dehydration, hypotension, drowsiness, confusion, or extreme hyperglycaemia. New suspected type 1 diabetes, especially with catabolism or ketones, needs same-day specialist-supported care. Severe hypoglycaemia requiring assistance, persistent low glucose, sepsis, acute coronary syndrome, stroke, or acute kidney injury also overrides routine review.
Refer promptly when classification is uncertain and would change therapy: rapid failure, recurrent ketosis, low BMI with catabolism, young onset with a strong multigenerational pattern, pancreatic disease, or immune-checkpoint-inhibitor exposure. Pregnancy planning, confirmed pregnancy, recurrent severe hypoglycaemia, impaired awareness, complex insulin, advanced CKD, rapidly falling eGFR, substantial albuminuria, resistant hypertension, and severe liver disease merit specialist or multidisciplinary input.
Organ-specific pathways matter. Sudden visual loss is urgent; routine retinal screening should occur even without symptoms. An ulcerated, infected, ischaemic, gangrenous, or hot swollen foot needs rapid multidisciplinary assessment. Refer for metabolic surgery or obesity pharmacotherapy only with long-term nutritional and medical follow-up. Diabetes distress, eating disorder, severe depression, cognitive decline, or inability to afford essential treatment requires mental-health and social support. A referral must state the clinical question and urgency and must not leave the patient without interim prescriptions, results ownership, or follow-up.
Red Flags
Hyperglycaemic crisis may present with polyuria, thirst, weakness, vomiting, abdominal pain, dehydration, Kussmaul breathing, fruity breath, hypotension, drowsiness, confusion, seizures, or focal neurology. DKA is not excluded by type 2 labelling or a glucose below classic thresholds; SGLT2 inhibitors and pregnancy can produce euglycaemic DKA. HHS usually develops more gradually with profound water loss and hyperosmolality. Mixed DKA-HHS is common enough to measure ketones, pH, bicarbonate, electrolytes, and osmolality rather than infer the syndrome.
Severe hypoglycaemia is defined by need for assistance. Confusion, behavioural change, seizure, unconsciousness, or inability to swallow requires emergency treatment. Recurrent nocturnal episodes, impaired awareness, falls, or lows while driving demand urgent deintensification or regimen change. In CKD, insulin and some secretagogues can accumulate or outlast meals. A low HbA1c does not prove safe control.
Vascular and organ red flags include chest pain, focal neurological deficit, sudden breathlessness, abrupt visual loss, oliguria, pulmonary oedema, and a cold, black, infected, crepitant, or acutely deformed foot. Fever may be absent in serious infection. Pregnancy with hyperglycaemia, ketones, reduced fetal movement, or hypertension needs urgent obstetric-diabetes contact. Rapid unexplained deterioration, weight loss, jaundice, or pain radiating to the back can signal pancreatic disease. Running out of insulin or essential medicine because of cost or supply requires an immediate bridge plan, not delayed admonishment.
Indian Clinical Context
India's NP-NCD programme places diabetes screening, confirmation, initial management, longitudinal records, and referral within primary care and health-and-wellness-centre pathways. Population-based screening from age thirty can identify risk, but the screen must lead to a quality-assured diagnostic test and a reachable follow-up appointment. A capillary value obtained for screening should not be silently converted into a lifelong diagnosis. Registries should track confirmation and continuity, not just the number screened.
ICMR 2018 guidance provides a pragmatic Indian framework for lifestyle, medicines, and annual eye, kidney, and foot assessment. Its medication sequence predates some current cardiorenal outcome evidence, while international and ADA recommendations reflect different licensing, prices, and health systems. Use current Indian labels and formularies and explain where recommendations are extrapolated. Newer agents may be unavailable or unaffordable; an effective generic plan with reliable follow-up is safer than a theoretically superior prescription that cannot be continued.
Dietary counselling should fit household budgets, regional staples, religious fasting, shift work, and food availability. Replace sugary drinks and reduce refined excess without declaring culturally central foods forbidden. Physical activity advice must account for heat, safe space, manual work, retinopathy, neuropathy, and foot disease. Screen for tobacco in smoked and smokeless forms. Ask whether strips, HbA1c, UACR, retinal imaging, and transport are affordable before building a monitoring plan.
Team care can involve medical officers, nurses, pharmacists, dietitians, eye and foot services, and community health workers with consent and privacy safeguards. Use clear language and teach-back. Address stigma: type 2 diabetes is a biological disease shaped by genetics, environment, and access, not a moral defect. When resources are constrained, prioritise emergency recognition, sustainable glucose and blood-pressure treatment, statin eligibility, kidney assessment, foot protection, and referral for sight-threatening or limb-threatening disease.
NMC Competency Mapping
The NMC Medicine diabetes cluster spans chronic complications, clinical presentation, investigation, emergencies, and pharmacotherapy. IM11.7 addresses chronic complications; IM11.9 the clinical presentation; IM11.11 glucose, electrolytes, blood gas, ketones, and renal investigations; IM11.13 urinary ketone testing; IM11.15 diabetic emergencies and principles of therapy; and IM11.16 diabetes medicines. These outcomes integrate physiology, biochemistry, pathology, pharmacology, ophthalmology, surgery, obstetrics, paediatrics, and community medicine. Institutions must verify wording and performance levels against their authorised 2024 curriculum ledger.
A graduating learner should confirm diabetes with appropriate tests, identify HbA1c limitations, keep classification open when evidence is atypical, and recognise DKA or HHS. The learner should construct a baseline plan covering blood pressure, lipids, cardiovascular disease, eGFR, UACR, retina, neuropathy, feet, weight, smoking, vaccination, and psychosocial barriers. Supervised skills include capillary glucose and ketone testing, foot inspection, pulses and monofilament examination, injection teaching, and sick-day safety-netting.
Useful assessment rewards prioritisation rather than recall alone. An OSCE can ask the candidate to explain a new diagnosis and agree a cost-conscious first plan. A written case can test medicine selection in CKD or heart failure without assuming every newer drug is affordable. Another can require emergency recognition in an SGLT2-treated patient with vomiting and modest glucose. Completion does not certify independent pregnancy, crisis, or complex insulin management and does not substitute for MedNext Clinical Team review.
Key Exam Pearls for NEET PG
Diagnostic thresholds are HbA1c at least 6.5%, fasting plasma glucose at least 126 mg/dL, two-hour glucose at least 200 mg/dL after a 75-g OGTT, or random plasma glucose at least 200 mg/dL with classic symptoms or crisis. Confirm an abnormal result when unequivocal hyperglycaemia is absent. HbA1c is distorted by altered red-cell turnover, haemoglobin variants, pregnancy, transfusion, and some kidney states. A screening capillary value or glycosuria alone does not establish diabetes.
Type 1 diabetes can present in an adult with obesity. Rapid weight loss, ketosis, autoimmune disease, or fast non-insulin treatment failure should prompt reclassification. Type 3c diabetes follows pancreatic disease; monogenic diabetes may show young onset and a strong vertical family pattern. DKA combines ketonaemia and metabolic acidosis and may be euglycaemic with SGLT2 inhibitors. HHS features marked hyperosmolality and dehydration with minimal major ketoacidosis, although overlap occurs.
For many non-pregnant adults, HbA1c below 7% is reasonable, but targets are individualised. Microvascular complications are retinopathy, nephropathy, and neuropathy; UACR and eGFR provide complementary kidney information. SGLT2 inhibitors and selected GLP-1 receptor agonists may be chosen for cardiovascular or kidney benefit beyond glucose lowering. Metformin can contribute to vitamin B12 deficiency. Sulfonylureas and insulin cause hypoglycaemia. Pioglitazone can worsen oedema and heart failure. Pregnancy changes testing, targets, and medicine safety. The best answer integrates glycaemia, organ protection, weight, hypoglycaemia, renal function, pregnancy, cost, and patient preference.
Frequently Asked Questions
Does one abnormal HbA1c result always prove type 2 diabetes mellitus?
No. In an asymptomatic person without unequivocal hyperglycaemia, confirm the result promptly with a repeat or second diagnostic test. HbA1c can be misleading with anaemia, haemoglobin variants, altered red-cell turnover, pregnancy, transfusion, and some kidney conditions. Even when diabetes is confirmed, the clinical evidence must support classification as type 2.
Is metformin always the only correct first medicine for type 2 diabetes?
Metformin remains effective, inexpensive, and widely used, but first treatment is individualised. Established cardiovascular disease, heart failure, CKD, obesity, severe symptomatic hyperglycaemia, pregnancy, renal function, adverse effects, affordability, and supply can change the best choice. Lifestyle and risk-factor care continue whichever glucose-lowering medicine is selected.
Why are kidney and cardiovascular findings assessed at diagnosis?
Type 2 diabetes may exist for years before recognition, so albuminuria, reduced eGFR, retinopathy, neuropathy, or cardiovascular disease may already be present. These findings change blood-pressure, lipid, and glucose-lowering treatment and referral. UACR and eGFR are complementary; a normal creatinine alone does not exclude clinically important diabetic kidney disease.
What should a person with type 2 diabetes do during vomiting or acute illness?
Follow the individual written sick-day plan, maintain fluids and carbohydrate as tolerated, monitor glucose more often, and check ketones when DKA is possible. Some medicines require temporary pausing during dehydration, fasting, or severe illness. Persistent vomiting, deep breathing, drowsiness, dehydration, rising ketones, or inability to keep fluids down needs urgent assessment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic